List of Excipients in Branded Drug LOCOID

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	LOCOID	hydrocortisone butyrate	16781-382	ANHYDROUS CITRIC ACID
Bausch Health US LLC	LOCOID	hydrocortisone butyrate	16781-382	BUTYLPARABEN
Bausch Health US LLC	LOCOID	hydrocortisone butyrate	16781-382	CETETH-20
Bausch Health US LLC	LOCOID	hydrocortisone butyrate	16781-382	CETOSTEARYL ALCOHOL

LOCOID Excipient Strategy and Commercial Opportunities

Last updated: October 8, 2026

Locoid is a topical hydrocortisone butyrate product, generally supplied at 0.1% strength in cream, lotion, and ointment vehicles. Its commercial opportunity is no longer based primarily on active-ingredient exclusivity. The more viable strategies are vehicle performance, tolerability, preservative reduction, packaging, pediatric usability, and differentiated regulatory positioning.

The strongest product concepts are:

1. A preservative-free or low-preservative cream for sensitive and pediatric skin.
2. A rapidly spreading, low-grease emulsion with improved cosmetic acceptability.
3. A scalp and hairy-area lotion, foam, or spray with faster drying.
4. A barrier-compatible formulation for atopic dermatitis and chronic inflammatory dermatoses.
5. A differentiated generic or 505(b)(2) product supported by comparative skin-delivery and usability data.

Hydrocortisone butyrate is an established topical corticosteroid. The key commercial constraint is generic competition and the absence of a meaningful remaining composition-of-matter barrier. Excipient selection must therefore create measurable clinical, usability, or manufacturing value.

What is Locoid and which formulations are commercially relevant?

Locoid contains hydrocortisone butyrate, a topical corticosteroid classified as medium potency in the United States. The product is used for corticosteroid-responsive dermatoses, including inflammatory and pruritic skin conditions. FDA labeling identifies cream, lotion, and ointment dosage forms, with the precise marketed portfolio varying by jurisdiction and manufacturer [1].

Product attribute	Commercial relevance
Active ingredient	Hydrocortisone butyrate
Typical strength	0.1%
Therapeutic class	Topical corticosteroid
Main dosage forms	Cream, lotion, ointment
Primary users	Dermatology patients, caregivers, prescribers
Key treatment areas	Eczema, dermatitis, inflammatory dermatoses
Main formulation challenge	Balancing potency, skin delivery, tolerability, and cosmetic acceptability
Main market risk	Generic substitution and price competition
Biologic status	Not a biologic; biosimilar rules do not apply

The dosage form determines the excipient strategy. Creams are more suitable for broad-area use and patient acceptance. Ointments can improve occlusion and dryness but are often rejected for greasiness. Lotions spread rapidly and can work better on larger or hairy areas, but they may sting, dry, or feel less protective.

What excipients are used in Locoid formulations?

Locoid formulations use conventional topical excipients associated with emulsions, semisolids, humectancy, preservation, viscosity control, and skin feel. Public FDA labeling identifies excipient differences between dosage forms, which indicates that the vehicle is a core part of product differentiation rather than an incidental component [1,2].

Representative excipient functions include:

Excipient category	Typical function	Strategic implication
Mineral oil and petrolatum	Occlusion, emollience, barrier support	Improves dry-skin performance but can increase greasiness
Fatty alcohols	Consistency, emulsion stabilization, skin feel	Can improve body and spreadability
Glyceryl stearate	Emulsification and texture	Supports cream structure
Polyoxyl cetostearyl ether	Emulsification and stabilization	Allows oil-in-water cream design
Propylene glycol	Humectancy and solvent function	May improve hydration but can sting sensitive skin
Citric acid and sodium citrate	Buffering and pH control	Supports stability and tolerability
Carbomer	Rheology and suspension control	Useful for lotion viscosity and application profile
Alcohols or volatile solvents	Fast drying and spreadability	May increase sting or dryness
Parabens or alternative preservatives	Microbial protection	Central to preservative-free positioning
Purified water	Continuous phase	Requires robust microbial control

The exact composition, concentration, supplier grade, and process conditions are important. A formulation that uses the same excipients as Locoid can still differ materially through particle size, emulsion droplet distribution, pH, viscosity, preservative system, packaging, and manufacturing sequence.

What excipient strategy best supports a Locoid follow-on product?

The most defensible strategy is to select excipients around a defined patient or application problem rather than simply reproduce a known cream base.

Preservative-free or reduced-preservative cream

A preservative-free formulation could target patients with sensitive, atopic, or compromised skin. The main technical options are:

• Anhydrous or low-water ointment systems.
• Single-use packaging.
• Airless pumps with validated microbial protection.
• Sterile or low-bioburden manufacturing strategies where justified.
• Alternative preservation systems with lower irritation potential.

A water-rich cream without a preservative system creates microbial and in-use stability risks. The commercial claim should therefore be tied to validated package integrity, microbial challenge testing, in-use studies, and stability data.

Barrier-supportive emulsion

A cream could combine hydrocortisone butyrate with a lipid system intended to improve skin comfort. Candidate excipient classes include petrolatum, mineral oil, medium-chain triglycerides, ceramides, cholesterol, fatty acids, and phospholipid-based emulsifiers.

A barrier-supportive vehicle may have commercial value because corticosteroid users often have dry, inflamed, or barrier-impaired skin. However, a product that adds a new active skin-barrier ingredient may face a more complex regulatory and intellectual-property position. A simple excipient-only vehicle is generally easier to position as a generic or reformulated topical product.

Low-grease, fast-spreading cream

Patient acceptance is a major differentiator in topical dermatology. A low-grease cream can use:

• Lower petrolatum loading.
• Volatile or light emollients.
• Optimized oil-phase droplet size.
• Silicone-based slip agents, subject to regulatory and compatibility review.
• Structured emulsions that reduce residue without sacrificing occlusion.

The target should be quantifiable: shorter rub-in time, reduced residue, lower transfer to clothing, improved spread area, or higher patient preference in comparative testing.

Lotion for scalp and hairy areas

A lotion can be designed for large surface areas and hair-bearing sites. The formulation should prioritize:

• Low viscosity.
• Rapid wetting and spreading.
• Minimal flaking.
• Low residue.
• Reduced sting.
• Pump or metered-dose delivery.

A scalp-focused product has a distinct commercial position from a conventional cream. Packaging and actuator design may be as important as the excipient system.

What formulations are protected by Locoid-related intellectual property?

The original Locoid composition and formulation patents are old relative to the product’s commercial history. Hydrocortisone butyrate itself is not a new molecular entity, and the active ingredient is not expected to provide a current composition-of-matter barrier for ordinary generic development.

The remaining intellectual-property opportunity is more likely to arise from:

• Specific vehicle compositions.
• Particle-size or droplet-size controls.
• Non-aqueous or low-water systems.
• Foam, spray, gel, or aerosol delivery.
• Metered-dose packaging.
• Preservative-free container systems.
• Combination products.
• Manufacturing processes that produce defined rheological or delivery properties.
• Method-of-use claims covering particular patient populations or body sites.

A formulation patent is commercially stronger when it claims measurable technical parameters rather than a broad list of conventional excipients. Examples include defined ratios of oil-phase components, a narrow pH range, a specified viscosity profile, a controlled droplet-size distribution, or a package-formulation combination that materially improves stability.

For a US launch, the FDA Orange Book should be reviewed for current patent and exclusivity listings associated with the relevant hydrocortisone butyrate reference product [3]. Historical patents that are expired, delisted, or not listed in the Orange Book may still matter for freedom-to-operate only in limited circumstances, such as surviving foreign rights, process claims, or patent-term differences.

When does Locoid lose exclusivity?

Locoid’s core commercial exclusivity has already expired in the United States. The product is a small-molecule topical corticosteroid with generic competition. Market entry is therefore governed primarily by approval pathway, pharmaceutical equivalence, formulation similarity, manufacturing capacity, and commercial execution.

Exclusivity category	Locoid position
New chemical entity exclusivity	Expired or not applicable
Orphan-drug exclusivity	Not applicable
Biologic exclusivity	Not applicable
Core composition-of-matter protection	Historical; not a current barrier
Formulation exclusivity	Depends on specific patent and listing status
Pediatric exclusivity	No current strategic barrier identified
Generic competition	Established or commercially plausible
Biosimilar competition	Not applicable

A new formulation may obtain limited regulatory exclusivity if it qualifies under an applicable FDA pathway, but exclusivity would attach to the new product or indication rather than revive exclusivity for the original Locoid product.

What is the Orange Book status of Locoid?

The Orange Book is relevant to FDA-approved hydrocortisone butyrate reference products and any listed patents or exclusivity periods. The current status should be assessed by product-specific NDA, dosage form, and strength rather than by the Locoid brand name alone [3].

For a commercial program, the Orange Book review should document:

1. The reference-listed drug for each proposed dosage form.
2. Any listed patents and their expiration dates.
3. Whether the product has active exclusivity.
4. Whether an ANDA can use the 505(j) pathway.
5. Whether a 505(b)(2) application would be more appropriate because of a new dosage form, delivery system, or indication.

A conventional hydrocortisone butyrate cream that matches the reference product closely is more likely to fit an ANDA strategy. A foam, spray, novel package, or materially different vehicle may require a 505(b)(2) strategy, depending on the extent of formulation and clinical differences.

Which companies are challenging Locoid through generic competition?

Generic topical corticosteroid manufacturers commonly compete through ANDAs, contract development and manufacturing organizations, and private-label channels. The relevant competitive set includes companies with capabilities in:

• Semisolid topical manufacturing.
• Emulsion scale-up.
• Dermatology product development.
• Aluminum and laminate tube filling.
• Pump and airless-container systems.
• FDA ANDA submissions.
• Retail and pharmacy distribution.

Public FDA databases identify approved products and applicants, but commercial activity changes as products are discontinued, acquired, or supplied under private-label arrangements [4]. The most important competitive distinction is not the number of applicants. It is whether a supplier can maintain consistent rheology, assay, content uniformity, microbial quality, and physical stability at commercial scale.

What Paragraph IV challenges and litigation risks apply?

Paragraph IV risk depends on active Orange Book-listed patents associated with the reference product. A generic applicant may certify that a listed patent is invalid, unenforceable, or not infringed. If the reference sponsor brings suit within the statutory period, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and court action [5].

For Locoid-related products, the likely litigation exposure is lower for a conventional cream or lotion where core patents are expired. Risk can increase when a follow-on product relies on:

• A still-listed formulation patent.
• A patented delivery device.
• A narrow method-of-use claim.
• A process patent linked to a commercial manufacturing route.
• A patented combination with barrier-repair ingredients.

A Paragraph IV strategy should be supported by a claim chart covering composition, concentration, process steps, package configuration, and proposed labeling. Patent risk should not be assessed from the active ingredient alone.

How strong is the Locoid patent estate?

The legacy patent estate is likely weak as a barrier to ordinary generic entry but potentially relevant as a source of design-around information. The strongest new patent positions would focus on a differentiated vehicle or delivery system.

Patent subject	Likely strength
Hydrocortisone butyrate molecule	Low for new US exclusivity
Conventional cream with standard excipients	Low to moderate
Defined low-irritation preservative system	Moderate if technically supported
Preservative-free package-formulation system	Moderate to strong
Novel foam or spray delivery	Moderate to strong
Narrow manufacturing process	Moderate, subject to detectability
Broad method-of-use claim	Often vulnerable to validity and obviousness challenges
Barrier-supportive combination	Variable; stronger with clinical evidence

Formulation claims are most defensible when supported by comparative data. Useful evidence includes drug release, skin permeation, irritation, sensitization, rheology, spreadability, residue, and patient-preference results.

What FDA regulatory pathway is appropriate for a new Locoid product?

ANDA pathway

An ANDA is most suitable for a product that matches the reference-listed drug in active ingredient, strength, dosage form, route, and relevant performance attributes. The applicant must address pharmaceutical equivalence and bioequivalence requirements applicable to topical semisolid products [6].

The main development risks are:

• Failure to match the reference product’s microstructure.
• Differences in viscosity or phase behavior.
• Inadequate in vitro release performance.
• Inconsistent scale-up.
• Preservative or microbial-control failures.
• Device or package differences that affect dosing.

505(b)(2) pathway

A 505(b)(2) application may be more appropriate for a new Locoid vehicle, foam, spray, or package that cannot be fully bridged to the reference product through an ANDA. The applicant can rely partly on FDA findings for the listed drug while submitting additional data for the change [7].

Potential 505(b)(2) value propositions include:

• Faster application on hairy areas.
• Reduced application frequency.
• Lower irritation.
• Improved cosmetic acceptance.
• Novel delivery to a specific body site.
• Better dosing control.

The pathway does not guarantee approval or meaningful exclusivity. Product-specific clinical, pharmacokinetic, irritation, or usability data may be required.

What manufacturing and IP barriers affect commercial entry?

The main manufacturing barrier is reproducible semisolid performance at scale. Small changes in mixing energy, temperature, order of addition, cooling rate, homogenization, or raw-material grade can change:

• Droplet size.
• Viscosity.
• Drug distribution.
• Phase separation.
• Drug release.
• Spreadability.
• Long-term stability.

Excipient suppliers should be qualified for regulatory status, residual solvents, peroxide value, particle size, microbial quality, and lot-to-lot consistency. The formulation should be developed with multiple commercial-scale batches rather than relying on laboratory behavior.

Packaging creates a separate opportunity. Tubes are inexpensive and familiar but may expose the product to repeated air and user contact. Airless pumps can support lower-preservative systems and cleaner dosing, but they add device qualification, compatibility, extractables and leachables, dose-delivery, and cost requirements.

How does Locoid compare with competing topical corticosteroids?

Product class	Relative commercial position	Excipient opportunity
Hydrocortisone butyrate 0.1%	Established medium-potency option	Better tolerability, spreadability, and packaging
Hydrocortisone 1%	Lower-potency, high-volume market	OTC-style convenience and sensitive-skin positioning
Desonide	Low-potency prescription alternative	Pediatric and facial-use positioning
Triamcinolone acetonide	Broad strength and dosage-form competition	Cost-efficient creams and ointments
Mometasone furoate	Higher-potency option with broad dermatology use	Once-daily and high-acceptance vehicles
Betamethasone products	Higher-potency segment	Specialty delivery and combination products

Locoid is positioned between low-potency hydrocortisone products and stronger prescription corticosteroids. A new Locoid vehicle should not compete only on price. It should establish a use-case advantage, such as less greasy application, improved scalp use, lower irritation, or better adherence.

What commercial opportunities exist for Locoid excipients?

Retail generic opportunity

A low-cost cream or lotion can compete through pharmacy distribution and private-label contracts. The formulation should minimize raw-material complexity and use well-established excipients with multiple qualified suppliers.

Dermatology specialty opportunity

A differentiated vehicle can target dermatologists who prescribe medium-potency corticosteroids for eczema and dermatitis but encounter adherence problems related to messiness, stinging, or poor application on hair-bearing skin.

Pediatric opportunity

Pediatric positioning requires conservative excipient selection, clear age labeling, low irritation, and caregiver-friendly packaging. Fragrance-free, dye-free, low-sensitizer, and low-residue features may have commercial value, although each claim requires substantiation and regulatory review.

Contract development and manufacturing

A platform based on hydrocortisone butyrate could be adapted to other topical corticosteroids. The same emulsion, lotion, or airless-pump technology may support products containing hydrocortisone, desonide, triamcinolone acetonide, or other dermatology actives, subject to compatibility and regulatory requirements.

Combination products

Combining hydrocortisone butyrate with an antifungal, antibacterial agent, keratolytic, or barrier-supportive ingredient can expand clinical use but increases regulatory, clinical, stability, and patent complexity. The strongest commercial case is usually a defined condition with a recognized treatment gap rather than a broad combination claim.

What revenue exposure does Locoid create?

Locoid-specific revenue is difficult to infer from public company reporting because sales may be aggregated with broader dermatology portfolios, private-label products, or generic hydrocortisone butyrate products. The relevant market indicators are:

• Prescription volume by dosage form.
• Generic substitution rate.
• Average selling price.
• Retail versus specialty distribution.
• Formulation-specific demand.
• Payer restrictions.
• Prescriber preference.
• Manufacturer backorders and discontinuations.

The commercial value of a new excipient platform depends more on repeat use and channel access than on the price of hydrocortisone butyrate itself. A low-cost conventional generic can generate volume. A differentiated formulation requires evidence that the vehicle improves persistence, application frequency, patient preference, or prescribing behavior.

Key Takeaways

• Locoid is a hydrocortisone butyrate topical corticosteroid, typically supplied at 0.1%.
• Core active-ingredient exclusivity is no longer the principal commercial barrier.
• Conventional generic creams and lotions face substantial price competition.
• The strongest excipient opportunities are preservative reduction, barrier support, low-grease feel, scalp delivery, and improved packaging.
• An ANDA is most suitable for a conventional reference-matched product.
• A 505(b)(2) pathway may support a novel foam, spray, vehicle, package, or use profile.
• Formulation patents should claim measurable technical parameters and be supported by comparative data.
• Locoid is not a biologic, so biosimilar competition is not relevant.
• Manufacturing consistency, microstructure control, microbial protection, and package compatibility are central entry risks.
• The most attractive commercial strategy is a differentiated vehicle with documented usability and performance advantages over conventional hydrocortisone butyrate generics.

FAQs About Locoid Excipient and Commercial Strategy

Can a preservative-free Locoid cream be developed?

Yes. The most practical approaches are anhydrous or low-water systems, single-use packaging, airless pumps, or validated alternative preservation strategies. Microbial-control data and in-use stability are central to approval.

Which Locoid dosage form has the largest excipient opportunity?

A cream or lotion has the broadest opportunity. Creams allow barrier and cosmetic optimization, while lotions can target scalp and hairy areas where conventional creams are inconvenient.

Can a new Locoid formulation obtain FDA exclusivity?

Potentially, if it qualifies as a distinct approved product and satisfies applicable statutory requirements. Exclusivity would attach to the new formulation or indication, not to the historical Locoid molecule.

Are ceramides patentable in a hydrocortisone butyrate formulation?

Ceramides alone are unlikely to create a strong patent position. A stronger case requires a specific composition, concentration range, technical effect, and supporting comparative data.

Is Locoid suitable for a biosimilar development strategy?

No. Locoid contains a chemically synthesized small-molecule corticosteroid. A generic or 505(b)(2) strategy is more relevant than a biosimilar pathway.

References

1. U.S. Food and Drug Administration. (n.d.). Locoid Lipocream, hydrocortisone butyrate cream, prescribing information. DailyMed.
2. U.S. National Library of Medicine. (n.d.). Hydrocortisone butyrate topical product labeling. DailyMed.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.
5. U.S. Food and Drug Administration. (2017). Applications covered by section 505(b)(2). Guidance for Industry.
6. U.S. Food and Drug Administration. (2022). Physiological and in vitro evaluation of topical dermatological drug products submitted in ANDAs. Guidance for Industry.
7. U.S. Food and Drug Administration. (2020). ANDAs for certain highly purified synthetic peptides that reference listed drugs of recombinant origin. Guidance for Industry.
8. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.